Overview

Anti-Platelets in Chronic Obstructive Pulmonary Disease

Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This is a 6 week crossover study in smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Clopidogrel